胰岛素B链C端及B29Lys氨基在胰岛素促生长功能中的 …

利用结晶紫测定细胞生长的方法,在９６孔板培养的小鼠乳腺癌细胞ＧＲ２Ｈ６中,建立了胰岛素促细胞生长活力的测定体系。该方法具有灵敏度高,重复性好,操作简便,周期短及便于大量样品分析测试的优点。利用该方法研究了胰岛素Ｂ链Ｃ端延长与缩短的类似物和胰岛素侧链氨基对胰岛素促生长活性的影响。结果显示,胰岛素Ｂ链Ｃ端在胰岛素的促生长活性中有重要作用;Ｂ链２９Ｌｙｓ氨基对促生长活性也有较大贡献。     

胰岛素蛋白质工程：高活性［B10Asp］人胰岛素

用基因定位突变方法将胰岛素Ｂ链第１０位的Ｈｉｓ变为Ａｓｐ,获得高活力胰岛素──［Ｂ１０Ａｓｐ］人胰岛素。其受体结合能力和离体生物活力分别为猪胰岛素的２６２％和２３５％;体内生物活力也明显高于猪胰岛素;它的促细胞生长能力为猪胰岛素的１７４％。     

^3H—胸腺嘧啶核苷参入法测定胰岛素促生长活性

利用＾３Ｈ－胸腺嘧啶核苷参入方法,在２４孔板和９６孔板培养的小鼠乳腺癌细胞ＧＲ２Ｈ６中,建立了胰岛素促细胞生长活性的测定体系。这一方法具有操作简便、周期较短和便于进行大量样品分析和测试等优点,它为研究胰岛素促生长功能与结构的关系提供了适当的新研究体系。     

双链杂交分子“胰岛素－类胰岛素生长因子－I

以去Ｂ链Ｃ端八肽胰岛素（ＤＯＩ）和化学合成的ＩＧＦ－Ｉ的２２～２９（８肽）及２２－３２（１１肽）为底物,用酶促半合成方法制备了杂交分子“胰岛素－类胰岛素生长因子－Ｉ,Ｉｎｓ／ＩＧＦ－Ｉ（８）和Ｉｎｓ／ＩＧＦ－Ｉ（１１）。研究了它们的胰岛素生物活性,结果表明,猪胰岛素Ｂ链Ｃ端Ｂ２７的Ｔｈｒ被Ａｓｎ取代,Ｂ３０的Ａｌａ被Ｔｈｒ取代同时Ｂ２５～Ｂ２６及Ｂ２８－Ｂ２ｋ９氨基酸顺序颠倒以及在Ｂ链Ｃ末端延长３肽（Ｇｌｙ－Ｔｙｒ－Ｇｌｙ）都不影响胰岛素的生物活力。     

〔B25－Trp〕去B链C端五肽胰岛素酰胺的合成及性质

去Ｂ链Ｃ端八肽胰岛素（ＤＯＩ）与Ｇｌｙ－Ｐｈｅ－Ｔｒｐ－ＮＨ２通过胰蛋白酶催化缩合后,经分离纯化得到聚丙烯酰胺凝胶电泳均一的Ｂ２５－Ｔｒｐ取代的去Ｂ链Ｃ端五肽胰岛素酰胺（〔Ｂ２５－Ｔｒｙ〕ＤＰＩ－ＮＨ２）．酶促缩合率大于８５％,回收率为３６．２％。用小白鼠惊厥法测得〔Ｂ２５－Ｔｒｐ〕ＤＰＩ－ＮＨ２的体内活力约为天然胰岛素的７０％,用人胎盘细胞膜测得的其胰岛素受体结合能力为天然胰岛素的７２．５±２．４％;利用色氨酸和酪氨酸的内源荧光研究了此类似物的溶液构象．     

去B链羧端七肽人胰岛素的分离纯化及性质研究

在大肠杆菌温度诱导体系中以非融合方式进行去Ｂ链羧端七肽人胰岛素原基因的表达,获得去Ｂ链羧端七肽人胰岛素原,表达产物占细胞总蛋白量的１３％,表达产物经ＳｅｐｈａｄｅｘＧ－５０柱层析分离及胰蛋白酶和羧肽酶Ｂ的酶促转化等步骤,可得到纯度达９４％以上的去Ｂ链羧端七肽人胰岛素,其氨基酸组成与预期值相符,受体活性是标准猪胰岛素的１％．     

重组单链胰岛素的连接肽与其生物功能的关系

为研究重组单链胰岛素的生物活性与连接肽之间的关系,用基因定点突变的方法分别以二肽A-K,七肽A-A-A-A-A-A-K和十二肽A-A-A-A-A-A-A-A-A-A-A-K连接胰岛素的B30和A1,得到3个单链胰岛素分子PIP,[A]₅PIP和[A]₁₀PIP.它们的受体结合能力分别为胰岛素的0.14%, 14.3% 和11.1%, 体内生物活性与受体结合能力一致,而它们的促生长活性分别为胰岛素的17%,116.3%和38%.结果表明:(ⅰ)单链胰岛素也具有胰岛素的促代谢和促生长功能;(ⅱ)单链胰岛素与胰岛素受体的结合能力与连接肽的长度和氨基酸组成密切相关, 其受体结合能力随连接肽的改变,可由无到100%,进一步说明胰岛素与其受体结合时,B链C端远离A链N端是必需的;(ⅲ)单链胰岛素的促细胞生长能力也与连接肽长度和组成密切相关,且比其自身的促代谢能力强.     

双链杂交分子“胰岛素—类胰岛素生长因子—I”

以去Ｂ链Ｃ端八肽胰岛素和化学合成的ＩＧＦ－Ｉ的２２－２９及２２－３２为底物,用酶促半合成方法制备了杂交分子“胰岛素－类胰岛素茵子－Ｉ”,Ｉｎｓ／ＩＧＦ－Ｉ和Ｉｎｓ－ＩＧＦ－Ｉ。研究了它们的胰岛中生物活性。结果表明,猪胰岛素Ｂ链Ｃ端Ｂ２７的Ｔｈｒ被Ａｓｎ取代,Ｂ３０的Ａｌａ被Ａｌａ被Ｔｈｒ取代同时Ｂ２５－Ｂ２６及Ｂ２８－Ｂ２９氨基酸顺序颠紧及在Ｂ链Ｃ末端延长３肽都不影响胰岛素的生物活力。     

去B链羧端三肽人胰岛素的分离纯化及其性质研究

将去Ｂ链羧端三肽人胰岛素原基因克隆到表达质粒ｐＢＶ２２０上,在大肠杆菌系统中经温度诱导表达,表达产物占细胞总蛋白量的１２％,表达产物经ＳｅｐｈａｄｅｘＧ－５０柱层析分离以及胰蛋白酶和羧肽酶Ｂ的酶促转化等步骤,可得到去Ｂ链羧端三肽人胰岛素,其纯度达９３％,其氨基酸组成与预期值相符,但其受体结合活性仅是标准猪胰岛素的４５％．     

胰岛素的促生长作用

除了经典的代谢调节作用之外,胰岛素还具有重要的促生长作用：在体外胰岛素能够刺激众多细胞的增殖与分化,一些实验证明胰岛素在体内可能也是一种重要的生长调节因子.胰岛素的促生长作用通过细胞表面的胰岛素受体介导,但在较高的胰岛素浓度下也可以通过类胰岛素生长因子Ⅰ(IGF-Ⅰ)受体进行,在不同细胞体系中可能会有所不同.受体后的信号转导经过了一系列磷酸化和去磷酸化等途径,其中有胰岛素受体底物1(IRS-1)、Shc蛋白、Ras蛋白以及磷酸肌醇3激酶(PI3-K)等的参与.在胰岛素的分子表面很可能存在一些区域或位点,对其促生长作用有着更大的贡献,通过对一些高促生长活性的胰岛素类似物的研究已揭示出一些初步的证据.     

Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues

Background

Insulin analogues comprising acidic amino acid substitutions at position B10 have previously been shown to display increased mitogenic potencies compared to human insulin and the underlying molecular mechanisms have been subject to much scrutiny and debate. However, B10 is still an attractive position for amino acid substitutions given its important role in hexamer formation. The aim of this study was to investigate the relationships between the receptor binding properties as well as the metabolic and mitogenic potencies of a series of insulin analogues with different amino acid substitutions at position B10 and to identify a B10-substituted insulin analogue without an increased mitogenic to metabolic potency ratio.

Methodology/Principal Findings

A panel of ten singly-substituted B10 insulin analogues with different amino acid side chain characteristics were prepared and insulin receptor (both isoforms) and IGF-I receptor binding affinities using purified receptors, insulin receptor dissociation rates using BHK cells over-expressing the human insulin receptor, metabolic potencies by lipogenesis in isolated rat adipocytes, and mitogenic potencies using two different cell types predominantly expressing either the insulin or the IGF-I receptor were systematically investigated. Only analogues B10D and B10E with significantly increased insulin and IGF-I receptor affinities as well as decreased insulin receptor dissociation rates displayed enhanced mitogenic potencies in both cell types employed. For the remaining analogues with less pronounced changes in receptor affinities and insulin receptor dissociation rates, no apparent correlation between insulin receptor occupancy time and mitogenicity was observed.

Conclusions/Significance

Several B10-substituted insulin analogues devoid of disproportionate increases in mitogenic compared to metabolic potencies were identified. In the present study, receptor binding affinity rather than insulin receptor off-rate appears to be the major determinant of both metabolic and mitogenic potency. Our results also suggest that the increased mitogenic potency is attributable to both insulin and IGF-I receptor activation.     

一种新的胰岛素及生长因子促生长活性测定系统

ＧＲ２Ｈ６细胞是从小鼠乳腺癌细胞衍生来的成纤维细胞样细胞株。该细胞能在特定的无血清培养液中生长,我们发现在此无血清培养条件下,ＧＲ２Ｈ６细胞生长情况与胰岛素、表皮生长因子和类胰岛素生长因子－Ｉ的浓度有较好的相关性,根据细胞数目和ＤＮＡ总量的变化可定量测定胰岛素和上述生长因子对该细胞株的促生长作用。据此,本实验室建立了一种新的胰岛素与生长因子促生长活性测定系统。与已知的胰岛素和生长因子测活系统比较,     

一种重组抗胰蛋白酶单体人胰岛素突变体的设计、制备和鉴定

用缺口双链DNA的定向突变方法分别将胰岛素前体中B链第 2 2、2 8、2 9和 3 0位改变为Asp、Lys、Pro和Lys,酵母分泌表达的前体经胰蛋白酶直接酶切 ,得到重组 [B2 2Asp、B2 8Lys、B2 9Pro、B3 0Lys]人胰岛素。它与受体的结合能力约为猪胰岛素的 6% ,而体内生物活力保留 5 0 %。通过FPLC分子筛测定其自身结合能力 ,在生理条件下浓度达 10 -4mol/L时它以单体形式存在。作为可抗胰蛋白酶酶解的单体胰岛素类似物 ,它可能具有一定的应用前景     

The relationship between the connecting peptide of recombined single chain insulin and its biological function

To investigate the relationship between the biological activity of recombined single chain insulin and the length of the connecting peptide, we designed and prepared three single chain insulin molecules, namely, PIP, [A]5PIP and [A]10PIP, by site-directed mutagenesis, in which B30 and A1 were linked through dipeptide A-K, heptapeptide A-A-A-A-A-A-K, and dodecapeptide A-A-A-A-A-A-A-A-A-A-A-K, respectively. Their receptor binding capacities were 0.14%, 14.3% and 11.1% of that of insulin respectively and their in vivo biological activities were in consistence with their receptor binding capacity; whereas their growth promoting activities were 17%, 116.3% and 38% of that of insulin. These results suggested the following conclusions. (i) The recombined single chain insulin could also possess the same metabolic and mitogenic function as insulin. (ii) The receptor binding capacity of recombined single chain insulin to insulin receptor was closely related to the length and amino acid composition of the connectin     

The relationship between the connecting peptide of recombined single chain insulin and its biological function

To investigate the relationship between the biological activity of recombined single chain insulin and the length of the connecting peptide, we designed and prepared three single chain insulin molecules, namely, PIP, [A]₅PIP and [A]₁₀PIP, by site-directed mutagenesis, in which B30 and A1 were linked through dipeptide A-K, heptapeptide A-A-A-A-A-A-K, and dodecapeptide A-A-A-A-A-A-A-A-A-A-A-K, respectively. Their receptor binding capacities were 0.14%, 14.3% and 11.1% of that of insulin respectively and theirin vivo biological activities were in consistence with their receptor binding capacity; whereas their growth promoting activities were 17%, 116.3% and 38% of that of insulin. These results suggested the following conclusions. (i) The recombined single chain insulin could also possess the same metabolic and mitogenic function as insulin. (ii) The receptor binding capacity of recombined single chain insulin to insulin receptor was closely related to the length and amino acid composition of the connecting peptide and could change from 0 to 100% of insulin depending on the different connecting peptides. This result further illustrated the necessity of B chain C-terminus swaying away from A chain N-terminus when insulin binds to its receptor. (iii) The mitogenic activity of recombined single chain insulin also depended on the length and the amino acid composition of the connecting peptide and was higher than its metabolic activity.     

Structure and activity of insulin, XV[1-5]. Further evidence for the importance of arginine residue B22 in the activity of insulin. Semisyntheses of despentapeptide-(B23 - 30)-insulins varied in B22 using desnonapeptide-(B22 - 30)-insulin and tetrapeptides

Insulin hexamethyl ester was digested by trypsin. The resulting desoctapeptide-(B23 - 30)-insulin pentamethyl ester was purified. This compound was digested by carboxypeptidase B to remove the arginine residue B22 at the end of the B chain. Then the N-terminal amino groups of the remaining desnonapeptide-(B22 - 30)-insulin pentamethyl ester were protected with the Boc residue. The free carboxyl group of the glutamic acid residue B21 of this product was coupled to the following synthetic tetrapeptide esters: Arg-Gly-Phe-Phe-OMe, Lys(Boc)-Gly-Phe-Phe-OMe, Orn(Boc)-Gly-Phe-Phe-OMe, Cit-Gly-Phe-Phe-OMe, Ala-Gly-Phe-Phe-OMe and Gly-Gly-Phe-Phe-OMe. The syntheses of these peptide esters are described. After removal of all protecting groups, despentapeptide-insulin (B22-Arg) and analogues of this product with variation in position B22 could be obtained. They were purified by column chromatography. The biological activities of these components were determined by the mouse fall test. In the case of despentapeptide insulin (C-terminus Arg-Gly-Phe-Phe), the activity rose to the expected value of 34%. The insulin variants with amino acid residues other than arginine in position B22 had much lower activities: with lysine 13%, with ornithine 12%, with citrulline 9%, with alanine 8% and with glycine 6%. Desnonapeptide-insulin by itself posses an activity of 3%. These results demonstrate once more the essential nature of arginine residue B22 for insulin activity.     

Agonism and Antagonism at the Insulin Receptor

Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G protein-coupled receptors (GPCRs) and other receptors but in general, with the exception of antibodies, not for receptor tyrosine kinases (RTKs). In the case of the IR, no natural ligand or insulin analogue has been shown to exhibit antagonistic properties, with the exception of a crosslinked insulin dimer (B29-B’29). However, synthetic monomeric or dimeric peptides targeting sites 1 or 2 of the IR were shown to be either agonists or antagonists. We found here that the S961 peptide, previously described to be an IR antagonist, exhibited partial agonistic effects in the 1–10 nM range, showing altogether a bell-shaped dose-response curve. Intriguingly, the agonistic effects of S961 were seen only on mitogenic endpoints (³H-thymidine incorporation), and not on metabolic endpoints (¹⁴C-glucose incorporation in adipocytes and muscle cells). The agonistic effects of S961 were observed in 3 independent cell lines, with complete concordance between mitogenicity (³H-thymidine incorporation) and phosphorylation of the IR and Akt. Together with the B29-B’29 crosslinked dimer, S961 is a rare example of a mixed agonist/antagonist for the human IR. A plausible mechanistic explanation based on the bivalent crosslinking model of IR activation is proposed.     

Self-association of long-acting insulin analogues studied by size exclusion chromatography coupled to multi-angle light scattering

Two structurally very different insulin analogues analysed here, belong to a class of analogues of which two have been reported to have a protracted action through self-assembly to high molar mass in subcutis. The process of self-association of insulin analogues Lys(B29) (N(ε)ω-carboxyheptadecanoyl) des(B30) human insulin and Lys(B29) (N(ε)-lithocholyl) des(B30) human insulin was investigated using size exclusion chromatography (SEC) in connection with multi-angle light-scattering. Self-assembly to high molar mass was obtained by exchanging the formulation containing phenolic preservatives with an isotonic eluent during SEC. It was shown that increasing amounts of zinc in the formulations of the two analogues increased the size of the self assemblies formed during gel filtration. The addition of 0.2 mM phenol to the elution buffer slowed down the self-association process of zinc containing formulations and shed light on the initial association process. The results indicated that a dihexamer is a possible building block during self-association of Lys(B29) (N(ε)ω-carboxyheptadecanoyl) des(B30) human insulin. Surprisingly, in the absence of zinc the two analogues behaved very differently. Lys(B29) (N(ε)ω-carboxyheptadecanoyl) des(B30) human insulin was in equilibrium between oligomers smaller than a hexamer, whereas Lys(B29) (N(ε)-lithocholyl) des(B30) human insulin self-associated and formed even larger complexes than in the presence of zinc.     

Insulin analogues with permuted A chain N-terminus (author's transl)]

By partial synthesis insulin analogues were prepared in which the amino acid in position 1 of the A chain was permuted. Glycine in position A 1 was exchanged for leucine, tert.- butyloxycarbonylvaline, valine, proline, lysine as well as glutamic acid. Two pathways of partial synthesis were followed: Firstly, des-1-glycine-A-chain S-sulfonate was reacted with active esters of tert.-butyloxycarbonylamino acids. The ensuing modified A-chains were combined with natural B-chain to give A1-permuted insulins. In the second procedure, the preparation of tris-Boc-[A1-leucine]insulin was accomplished by reaction of Boc-leucine N-hydroxysuccinimide ester with NalphaB1,NepsilonB29-bis(tert.-butyloxycarbonyl)-des-A1-glycine-insulin. The protected insulin derivative had been prepared by combination of des-glycine-A-chain with Nalpha1,Nepsilon29-bis(tert.-butyloxycarbonyl)-B-chain. The deprotected analogues differed considerably in their CD-spectra from insulin and possessed low in vitro biological activities of 2.5-17%. Crystallization attempts failed. Thus, the introduction of side chains in position A1 distorts the conformation sterically and decreases the biological activity.